Circulating antiandrogenic activity in children with congenital adrenal hyperplasia during peroral flutamide treatment

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 9, 2005, Pages 5140-5145

  Hero, Matti ^a   Jänne, Olli A ^a,b   Näntö Salonen, Kirsti ^c   Dunkel, Leo ^a,d   Raivio, Taneli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b BIOMEDICUM HELSINKI   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANDROGEN RECEPTOR; DRUG METABOLITE; FLUDROCORTISONE; FLUTAMIDE; GONADORELIN DERIVATIVE; HYDROCORTISONE; LETROZOLE; PROCREN; TESTOSTERONE; UNCLASSIFIED DRUG; ANDROGEN; ANTIANDROGEN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ARTICLE; BODY HEIGHT; BONE MATURATION; CELL ASSAY; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG MONITORING; DRUG SAFETY; FEMALE; FINLAND; FOLLOW UP; HORMONE INHIBITION; HUMAN; MALE; MONKEY; NONHUMAN; OUTCOMES RESEARCH; PEDIATRIC HOSPITAL; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SUPPLEMENTATION; TESTOSTERONE BLOOD LEVEL; UNIVERSITY HOSPITAL; VELOCITY; BIOASSAY; BLOOD; CHILD; DOSE RESPONSE; DRUG INTERACTION; ORAL DRUG ADMINISTRATION; OSMOLARITY;

ADMINISTRATION, ORAL; ADRENAL HYPERPLASIA, CONGENITAL; ANDROGEN ANTAGONISTS; ANDROGENS; BIOLOGICAL ASSAY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FLUTAMIDE; HUMANS; MALE; OSMOLAR CONCENTRATION; PROSPECTIVE STUDIES; TESTOSTERONE;

EID: 24344444078     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0324     Document Type: Article

References (35)

1. Labrie F, Dupont A, Cusan L, Manhes G, Bergeron N, Lacourciere Y, Pineault S, Belanger A, Monfette G, Emond J 1989 Combination therapy with castration and flutamide: today's treatment of choice for prostate cancer. J Steroid Biochem 33:817-821
2. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424
3. Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD 1997 Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49:71-78
4. Caine M, Perlberg S, Gordon R 1975 The treatment of benign prostatic hypertrophy with flutamide (SCH: 13521): a placebo-controlled study. J Urol 114:564-568
5. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G 1998 Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 83:99-102
6. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ 1998 The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. J Clin Endocrinol Metab 83:2699-2705
7. Ibanez L, Potau N, Marcos MV, de Zegher F 2000 Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 85:3251-3255
8. Paoletti AM, Cagnacci A, Orru M, Ajossa S, Guerriero S, Melis GB 1999 Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Fertil Steril 72:448-453
9. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R 2000 Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 85:89-94
10. Muderris, II, Bayram F, Guven M 2000 A prospective, randomized trial comparing flutamide (250 mg/d) and finasteride (5 mg/d) in the treatment of hirsutism. Fertil Steril 73:984-987
11. Thiboutot D, Chen W 2003 Update and future of hormonal therapy in acne. Dermatology 206:57-67
12. Merke DP, Keil MF, Jones JV, Fields J, Hill S, Cutler Jr GB 2000 Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 85:1114-1120
13. Joint LWPES/ESPE CAH Working Group (Writing Committee: Clayton PE MW, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW) 2002 Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 87:4048-4053
14. Katchen B, Buxbaum S 1975 Disposition of a new, nonsteroid, antiandrogen, α, α, α-trifluoro-2-methyl-4′-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J Clin Endocrinol Metab 41:373-379
15. Ibanez L, De Zegher F 2003 Flutamide-metformin therapy to reduce fat mass in hyperinsulinemic ovarian hyperandrogenism: effects in adolescents and in women on third-generation oral contraception. J Clin Endocrinol Metab 88:4720-4724
16. Bertelloni S, Baroncelli GI, Sorrentino MC, Costa S, Battini R, Saggese G 1997 Androgen-receptor blockade does not impair bone mineral density in adolescent females. Calcif Tissue Int 61:1-5
17. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, Labrie F 1992 Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. Am J Med 92:465-470
18. Wysowski DK, Freiman JP, Tourtelot JB, Horton 3rdML1993 Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 118:860-864
19. Andrade RJ, Lucena MI, Fernandez MC, Suarez F, Montero JL, Fraga E, Hidalgo F 1999 Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet 353:983
20. Fau D, Eugene D, Berson A, Letteron P, Fromenty B, Fisch C, PessayreD1994 Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J Pharmacol Exp Ther 269:954-962
21. Takashima E, Iguchi K, Usui S, Yamamoto H, Hirano K 2003 Metabolite profiles of flutamide in serum from patients with flutamide-induced hepatic dysfunction. Biol Pharm Bull 26:1455-1460
22. Fukushima DK, Levin J, Kream J, Freed SZ, Whitmore WF, Hellman L, Zumoff B 1978 Effect of flutamide on cortisol metabolism. J Clin Endocrinol Metab 47:788-791
23. Charmandari E, Calis KA, Keil MF, Mohassel MR, Remaley A, Merke DP 2002 Flutamide decreases cortisol clearance in patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 87:3197-3200
24. Fukushima DK, Smulowitz M, Levin J 1980 Further studies on the effects of flutamide on cortisol metabolism. Steroids 35:209-217
25. Raivio T, Palvimo JJ, Dunkel L, Wickman S, Jänne OA 2001 Novel assay for determination of androgen bioactivity in human serum. J Clin Endocrinol Metab 86:1539-1544
26. Tanner J 1962 Growth at adolescence. 2nd ed. Oxford, UK: Blackwell, Inc.
27. Apter D, Jänne O, Karvonen P, Vihko R 1976 Simultaneous determination of five sex hormones in human serum by radioimmunoassay after chromatography on Lipidex-5000. Clin Chem 22:32-38
28. Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L 2001 A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial. Lancet 357:1743-1748
29. Matthews JN, Altman DG, Campbell MJ, Royston P 1990 Analysis of serial measurements in medical research. BMJ 300:230-235
30. Merke DP, Cutler Jr GB 1997 New approaches to the treatment of congenital adrenal hyperplasia. JAMA 277:1073-1076
31. Niopas I, Daftsios AC 2001 Determination of 2-hydroxyflutamide in human plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. J Chromatogr B Biomed Sci Appl 759:179-183
32. Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M, Castello R, Moghetti P 2000 Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab 85:81-84
33. Venturoli S, Paradisi R, Bagnoli A, Colombo FM, Ravaioli B, Vianello F, Mancini F, Gualerzi B, Porcu E, SeracchioliR2001 Low-dose flutamide (125 mg/day) as maintenance therapy in the treatment of hirsutism. Horm Res 56:25-31
34. Jasuja R, Ramaraj P, Mac RP, Singh AB, Storer TW, Artaza J, Miller A, Singh R, Taylor WE, Lee ML, Davidson T, Sinha-Hikim I, Gonzalez-Cadavid N, Bhasin S 2005 Delta-4-androstene-3,17-dione binds androgen receptor, promotes myogenesis in vitro, and increases serum testosterone levels, fat-free mass, and muscle strength in hypogonadal men. J Clin Endocrinol Metab 90:855-863
35. Mindnich R, Moller G, Adamski J 2004 The role of 17 β-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 218:7-20